PNC Financial Services Group Inc. Increases Holdings in IQVIA Holdings Inc. $IQV

PNC Financial Services Group Inc. lifted its position in shares of IQVIA Holdings Inc. (NYSE:IQV) by 17.5% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 54,691 shares of the medical research company’s stock after acquiring an additional 8,154 shares during the quarter. PNC Financial Services Group Inc.’s holdings in IQVIA were worth $12,328,000 at the end of the most recent quarter.

Several other institutional investors have also modified their holdings of IQV. Ameliora Wealth Management Ltd. purchased a new stake in shares of IQVIA during the 4th quarter worth approximately $25,000. Physician Wealth Advisors Inc. lifted its stake in IQVIA by 1,340.0% in the 3rd quarter. Physician Wealth Advisors Inc. now owns 144 shares of the medical research company’s stock valued at $27,000 after buying an additional 134 shares in the last quarter. International Assets Investment Management LLC purchased a new stake in IQVIA in the 4th quarter valued at approximately $27,000. Westside Investment Management Inc. lifted its stake in IQVIA by 219.6% in the 3rd quarter. Westside Investment Management Inc. now owns 147 shares of the medical research company’s stock valued at $30,000 after buying an additional 101 shares in the last quarter. Finally, Measured Wealth Private Client Group LLC purchased a new stake in IQVIA in the 3rd quarter valued at approximately $30,000. Hedge funds and other institutional investors own 89.62% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts recently issued reports on IQV shares. Citigroup reduced their target price on IQVIA from $230.00 to $200.00 and set a “neutral” rating on the stock in a research note on Friday, February 6th. Barclays raised IQVIA from an “equal weight” rating to an “overweight” rating and set a $210.00 target price on the stock in a research note on Friday, March 6th. Truist Financial reduced their target price on IQVIA from $290.00 to $245.00 and set a “buy” rating on the stock in a research note on Thursday, February 19th. BMO Capital Markets set a $250.00 target price on IQVIA in a research note on Friday, February 6th. Finally, Morgan Stanley set a $225.00 target price on IQVIA in a research note on Thursday, May 7th. Two analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and two have issued a Hold rating to the company. According to data from MarketBeat, the company has a consensus rating of “Buy” and an average target price of $225.69.

IQVIA Trading Up 0.2%

Shares of IQVIA stock opened at $168.28 on Friday. The firm has a market cap of $28.09 billion, a PE ratio of 20.85, a P/E/G ratio of 1.61 and a beta of 1.18. The company has a quick ratio of 0.75, a current ratio of 0.75 and a debt-to-equity ratio of 2.20. The business’s fifty day moving average is $169.72 and its two-hundred day moving average is $197.56. IQVIA Holdings Inc. has a fifty-two week low of $134.65 and a fifty-two week high of $247.04.

IQVIA (NYSE:IQV) last released its quarterly earnings data on Tuesday, May 5th. The medical research company reported $2.90 EPS for the quarter, topping analysts’ consensus estimates of $2.83 by $0.07. The business had revenue of $4.15 billion during the quarter, compared to the consensus estimate of $4.10 billion. IQVIA had a return on equity of 30.50% and a net margin of 8.33%.The business’s revenue for the quarter was up 8.4% on a year-over-year basis. During the same period in the prior year, the firm posted $2.70 EPS. IQVIA has set its FY 2026 guidance at 12.650-12.950 EPS. Analysts anticipate that IQVIA Holdings Inc. will post 11.57 earnings per share for the current year.

IQVIA announced that its board has approved a share repurchase program on Thursday, May 7th that permits the company to buyback $2.00 billion in shares. This buyback authorization permits the medical research company to purchase up to 6.8% of its stock through open market purchases. Stock buyback programs are generally an indication that the company’s leadership believes its stock is undervalued.

About IQVIA

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real?world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real?world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.